---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-040537"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:55:12.416015+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio reports Q4 2022 net loss of $7.7M; advances buntanetap trials

## Summary
- Net loss Q4 2022 of $7.7M vs $5.9M in Q4 2021; full-year net loss $25.3M vs $14.5M.
- Cash and equivalents $28.4M as of Dec 31, 2022; R&D spend $6.2M in Q4, up 114% YoY.
- FDA authorized Phase 2/3 Alzheimer's trial; EU sites approved for Phase 3 Parkinson's trial.
- Interim analysis for Phase 3 PD trial based on 132 patients; company proceeds as planned.
- Appointed VP Process Chemistry and VP Toxicology; filed patent for neuropsychiatric uses.

## SEC filing metadata
- accession: 0001104659-23-040537
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/0001104659-23-040537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/tm2311180d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-040537
- JSON: https://secwatch.observer/filing/0001104659-23-040537.json
- Plain text: https://secwatch.observer/filing/0001104659-23-040537.txt

## Key facts
- Earnings Releases
  Annovis Bio, Inc. reported the quarter and year ended December 31, 2022 results: net income net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021.
  - Period: the quarter and year ended December 31, 2022
  - Net income: net loss of $7.7 million, compared to a net loss of $5.9 million for the same period in 2021
  - Result: reported results
  source text: On April 3, 2023, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/0001104659-23-040537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.